Pharmacological treatment of abdominal aortic aneurysm

Cardiovascular Research

Volumn 83, Issue 3, 2009, Pages 436-443

  Miyake, Takashi ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Abdominal aortic aneurysm; Decoy; Ets; NF B; Pharmacology

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ATORVASTATIN; CAPTOPRIL; CELECOXIB; CERIVASTATIN; CROMOGLYCATE DISODIUM; CYCLOOXYGENASE 1 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOSARTAN; MACROLIDE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGODEOXYNUCLEOTIDE; PLACEBO; RAPAMYCIN; ROXITHROMYCIN; SIMVASTATIN; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TETRACYCLINE DERIVATIVE; TRANILAST; VALSARTAN; VITAMIN;

ABDOMINAL AORTA ANEURYSM; ADVENTITIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA WALL; APOPTOSIS; CHLAMYDIAL PNEUMONIA; CHRONIC INFLAMMATION; CLINICAL TRIAL; DISEASE COURSE; DRUG TARGETING; ENZYME INHIBITION; FOLLOW UP; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; INFLAMMATORY CELL; MARFAN SYNDROME; MAST CELL DEGRANULATION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; TUNICA MEDIA; UPREGULATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-BACTERIAL AGENTS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; CARDIOVASCULAR AGENTS; DRUGS, INVESTIGATIONAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; REMISSION INDUCTION; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 67651120034     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp155     Document Type: Review

References (81)

1. Lederle FA, Johnson GR, Wilson SE, Chute EP, Hye RJ, Makaroun MS et al. The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 2000; 160:1425-1430.
2. Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RA et al. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet 2002;360:1531-1539.
3. Hallett JW Jr. Management of abdominal aortic aneurysms. Mayo Clin Proc 2000;75:395-399.
4. Darling RC. Ruptured arteriosclerotic abdominal aortic aneurysms: a pathologic and clinical study. Am J Surg 1970;119:397-401.
5. Glima°ker H, Holmberg L, Elvin A, Nybacka O, Almgren B, Björck CG et al. Natural history of patients with abdominal aortic aneurysms. Eur J Vasc Surg 1991;5:125-130.
6. Lederle FA, Johnson GR, Wilson SE, Chute EP, Littooy FN, Bandyk D et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 1997;126:441-449.
7. Boll AP, Verbeek AL, van de Lisdonk EH, van der Vliet JA. High prevalence of abdominal aortic aneurysm in a primary care screening programme. Br J Surg 1998;85:1090-1094.
8. The UK Small Aneurysm Trial Participants. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet 1998;352: 1649-1655.
9. Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher CWet al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002;346:1437-1444.
10. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1995;15:1145-1151.
11. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000;105:1605-1612.
12. Saraff K, Babamusta F, Cassis LA, Daugherty A. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23:1621-1626.
13. Kato H, Iwai N, Inui H, Kimoto K, Uchiyama Y, Inagami T. Regulation of vascular angiotensin release. Hypertension 1993;21:446-454.
14. Schonbeck U, Sukhova GK, Gerdes N, Libby P. T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm. Am J Pathol 2002;161:499-506.
15. Watanabe N, Arase H, Kurasawa K, Iwamoto I, Kayagaki N, Yagita H et al. Th1 and Th2 subsets equally undergo Fas-dependent and -independent activation-induced cell death. Eur J Immunol 1997;27:1858-1864.
16. Tsuruda T, Kato J, Hatakeyama K, Kojima K, Yano M, Yano Y et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res 2008;102:1368-1377.
17. Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G et al. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Bio Chem 2005; 280:9291-9296.
18. Sun J, Sukhova GK, Yang M, Wolters PJ, MacFarlane LA, Libby P et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest 2007;117:3359-3368.
19. Leskinen MJ, Kovanen PT, Lindstedt KA. Regulation of smooth muscle cell growth, function and death in vitro by activated mast cells-a potential mechanism for the weakening and rupture of atherosclerotic plaques. Biochem Pharmacol 2003;66:1493-1498.
20. Nakae S, Suto H, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cells enhance T cell activation: importance of mast cell-derived TNF. Proc Natl Acad Sci USA 2005;102:6467-6472.
21. Elmore JR, Keister BF, Franklin DP, Youkey JR, Carey DJ. Expression of matrix metalloproteinases and TIMPs in human abdominal aortic aneurysms. Ann Vasc Surg 1998;12:221-228.
22. Crowther M, Goodall S, Jones JL, Bell PR, Thompson MM. Localization of matrix metalloproteinase 2 within the aneurysmal and normal aortic wall. Br J Surg 2000;87:1391-1400.
23. Curci JA, Liao SX, Huffman MD, Shapiro SD, Thompson RW. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest 1998;102:1900-1910.
24. Tamarina NA, McMillan WD, Shively VP, Pearce WH. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery 1997;122:264-271.
25. Mao D, Lee JK, VanVickle SJ, Thompson RW. Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture. Biochem Biophys Res Commun 1999;261:904-910.
26. Nollendorfs A, Greiner TC, Nagase H, Baxter BT. The expression and localization of membrane type-1 matrix metalloproteinase in human abdominal aortic aneurysms. J Vasc Surg 2001;34:316-322.
27. Goodall S, Crowther M, Hemingway DM, Bell PR, Thompson MM. Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation 2001;104: 304-309.
28. McMillan WD, Tamarina NA, Cipollone M, Johnson DA, Parker MA, Pearce WH. Size matters: the relationship between MMP-9 expression and aortic diameter. Circulation 1997;96:2228-2232.
29. Petersen E, Gineitis A, Wagberg F, Angquist KA. Activity of matrix metalloproteinase-2 and -9 in abdominal aortic aneurysms. Relation to size and rupture. Eur J Vasc Endovasc Surg 2000;20:457-461.
30. Defawe OD, Colige A, Lambert CA, Munaut C, Delvenne P, Lapiere CM et al. TIMP-2 and PAI-1 mRNA levels are lower in aneurysmal as compared to athero-occlusive abdominal aortas. Cardiovasc Res 2003;60:205-213.
31. Abisi S, Burnand KG, Waltham M, Humphries J, Taylor PR, Smith A. Cysteine protease activity in the wall of abdominal aortic aneurysms. J Vasc Surg 2007;46:1260-1266.
32. Lindholt JS, Erlandsen EJ, Henneberg EW. Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms. Br J Surg 2001;88:1472-1475.
33. Satta J, Juvonen T Haukipuro K, Juvonen M, Kairaluoma MI. Increased turnover of collagen in abdominal aortic aneurysms, demonstrated by measuring the concentration of the aminoterminal propeptide of type III procollagen in peripheral and aortal blood samples. J Vasc Surg 1995;22:155-160.
34. Bode MK, Soini Y, Melkko J, Satta J, Risteli L, Risteli J. Increased amount of type III pN-collagen in human abdominal aortic aneurysms: evidence for impaired type III collagen fibrillogenesis. J Vasc Surg 2000;32:1201-1207.
35. Krettek A, Sukhova GK, Libby P. Elastogenesis in human arterial disease: a role for macrophages in disordered elastin synthesis. Arterioscler Thromb Vasc Biol 2003;23:582-587.
36. Miller FJ Jr, Sharp WJ, Fang X, Oberley LW, Oberley TD, Weintraub NL. Oxidative stress in human abdominal aortic aneurysms: a potential mediator of aneurysmal remodeling. Arterioscler Thromb Vasc Biol 2002;22:560- 565.
37. McCormick ML, Gavrila D, Weintraub NL. Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2007;27:461-469.
38. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J Clin Invest 1996;98:2572-2579.
39. Li PF, Dietz R, von Harsdorf R. Reactive oxygen species induce apoptosis of vascular smooth muscle cell. FEBS Lett 1997;404:249-252.
40. Zhang J, Schmidt J, Ryschich E, Mueller-Schilling M, Schumacher H, Allenberg JR. Inducible nitric oxide synthase is present in human abdominal aortic aneurysm and promotes oxidative vascular injury. J Vasc Surg 2003;38:360-367.
41. Steinmetz EF, Buckley C, Shames ML, Ennis TL, Vanvickle-Chavez SJ, Mao D et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 2005;241:92-101.
42. Kalyanasundaram A, Elmore JR, Manazer JR, Golden A, Franklin DP, Galt SW et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg 2006;43:117-124.
43. Nagashima H, Aoka Y, Sakomura Y, Sakuta A, Aomi S, Ishizuka N et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 2002;36:158-163.
44. Sukhija R, Aronow WS, Sandhu R, Kakar P, Babu S. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 2006;97:279-280.
45. Schouten O, van Laanen JH, Boersma E, Vidakovic R, Feringa HH, Dunkelgrun M et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006;32: 21-26.
46. Liao S, Miralles M, Kelley BJ, Curci JA, Borhani M, Thompson RW. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 2001;33: 1057-1064.
47. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 2006;368:659-665.
48. Daugherty A, Manning MW, Cassis LA. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 2001;134:865-870.
49. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312:117-121.
50. Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369: 1431-1439.
51. Fujiwara Y, Shiraya S, Miyake T, Yamakawa S, Aoki M, Makino H et al. Inhibition of experimental abdominal aortic aneurysm in a rat model by an angiotensin receptor blocker, valsartan. Int J Mol Med 2008;22:703-708.
52. Lindholt JS, Juul S, Vammen S, Lind I, Fasting H, Henneberg EW. Immunoglobulin A antibodies against Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysm. Br J Surg 1999;86:634-638.
53. Vammen S, Lindholt JS, Ostergaard L, Fasting H, Henneberg EW. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg 2001;88:1066-1072.
54. Mosorin M, Juvonen J, Biancari F, Satta J, Surcel HM, Leinonen M et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001;34:606-610.
55. Lawrence DM, Singh RS, Franklin DP, Carey DJ, Elmore JR. Rapamycin suppresses experimental aortic aneurysm growth. J Vasc Surg 2004;40: 334-338.
56. Holmes DR, Wester W, Thompson RW, Reilly JM. Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg 1997;25:810-815.
57. Walton LJ, Franklin IJ, Bayston T, Brown LC, Greenhalgh RM, Taylor GW et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999;100:48-54.
58. King VL, Trivedi DB, Gitlin JM, Loftin CD. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 2006;26: 1137-1143.
59. Gitlin JM, Trivedi DB, Langenbach R, Loftin CD. Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res 2007;73:227-236.
60. Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun Nterminal kinase. Nat Med 2005;11:1330-1338.
61. Miyake T, Aoki M, Masaki H, Kawasaki T, Oishi M, Kataoka K et al. Regression of abdominal aortic aneurysms by simultaneous inhibition of nuclear factor kappaB and ets in a rabbit model. Circ Res 2007;101:1175- 1184.
62. Nakashima H, Aoki M, Miyake T, Kawasaki T, Iwai M, Jo N et al. Inhibition of experimental abdominal aortic aneurysm in the rat by use of decoy oligodeoxynucleotides suppressing activity of NFkB and ets transcription factors. Circulation 2004;109:132-138.
63. Miyake T, Aoki M, Nakashima H, Kawasaki T, Oishi M, Kataoka K et al. Prevention of abdominal aortic aneurysms by simultaneous inhibition of NFkappaB and ets using chimeric decoy oligonucleotides in a rabbit model. Gene Ther 2006;13:695-704.
64. Latchman DS. Transcription-factor mutations and disease. N Engl J Med 1996;334:28-33.
65. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor 'decoy' strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998;82:1023-1028.
66. Shiraya S, Miwa K, Aoki M, Miyake T, Oishi M, Kataoka K et al. Hypertension accelerated experimental abdominal aortic aneurysm through upregulation of nuclear factor kappaB and ets. Hypertension 2006;48:628-636.
67. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 1990;10: 2327-2334.
68. Satriano J, Schlondorff D. Activation of attenuation of transcriptional factor NF-kB in mouse glomerular cells in response to tumor necrosis factor-a, immunoglobulin G, and adenosine 30:50-cyclic monophosphate. J Clin Invest 1994;94:1629-1636.
69. Weber C, Erl W, Pietsch A, Weber PC. Aspirin inhibits nuclear factorkappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 1995;91:1914-1917.
70. Ledebur HC, Parks TP. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. J Biol Chem 1995;270:933-943.
71. Bond M, Baker AH, Newby AC. Nuclear factor kappaB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 1999;264:561-567.
72. Takeshita H, Yoshizaki T, Miller WE, Sato H, Furukawa M, Pagano JS et al. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 2. J Virol 1999;73:5548-5555.
73. Kim H, Koh G. Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2000;269:401-405.
74. Kuang PP, Berk JL, Rishikof DC, Foster JA, Humphries DE, Ricupero DA et al. NF-kappaB induced by IL-1beta inhibits elastin transcription and myofibroblast phenotype. Am J Physiol Cell Physiol 2002;283:C58- C65.
75. Kouba DJ, Chung KY, Nishiyama T, Vindevoghel L, Kon A, Klement JF et al. Nuclear factor-kappa B mediates TNF-alpha inhibitory effect on alpha 2(I) collagen (COL1A2) gene transcription in human dermal fibroblasts. J Immunol 1999;162:4226-4234.
76. Kavurma MM, Bobryshev YY, Khachigian LM. Ets-1 positively regulates Fas ligand transcription via co-operative interactions with Sp1. J Biol Chem 2002;277:36244-36252.
77. Sevilla L, Zaldumbide A, Carlotti F, Dayem MA, Pognonec P, Boulukos KE. Bcl-XL expression correlates with primary macrophage differentiation, activation of functional competence, and survival and results from synergistic transcriptional activation. J Biol Chem 2001;276:17800-17807.
78. Vandenbunder B, Wernert N, Queva C, Desbiens X, Stehelin D. Does the transcription factor c-ets1 take part in the regulation of angiogenesis and tumor invasion? Folia Biol (Praha) 1994;40:301-313.
79. Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M et al. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 1996;271:10672-10680.
80. Watabe T, Yoshida K, Shindoh M, Kaya M, Fujikawa K, Sato H et al. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer 1998;77:128-137.
81. Czuwara-Ladykowska J, Sementchenko VI, Watson DK, Trojanowska M. Ets1 is an effector of the transforming growth factor beta (TGF-beta) signaling pathway and an antagonist of the profibrotic effects of TGF-beta. J Biol Chem 2002;277:20399-20408.